1
|
Sicre De Fontbrune F, Barraco F, Dalle J, Forcade E, Terriou L, Berceanu A, Lebon D, Thépot S, Abraham J, Fahd M, Lioure B, Contejean A, Moluçon Chabrot C, Leblanc T, Leclerc-Teffahi S, Affinito S, Kamar D, Havet A, Bénard S, Regis P. Suivi de l’utilisation de l’Eltrombopag en vie réelle en France à partir des données de l’Observatoire National de l’Insuffisance Médullaire (RIME) : étude REVEPI. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.10.272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
2
|
Braun T, Debache A, Roudot H, Lusina D, Thépot S, Eclache V, Martin A, Soret J, Bréchignac S, Kelaidi C, Adès L, Fenaux P, Gardin C. 205 A SINGLE CENTER REPORT OF THERAPEUTIC STRATEGIES IN PATIENTS WITH ATYPICAL CML (ACML) AND UNCLASSIFIED MDS/MPN (MDS/MPN-U). Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30206-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
3
|
Corby A, Geneviève F, Baranger-Papot L, Bouvier A, Hunault-Berger M, Ifrah N, Thépot S. 185 SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA AFTER CHRONIC MYELOMONOCYTIC LEUKEMIA: AN UNCOMMON CASE REPORT OF CLONAL EVOLUTION. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30186-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
4
|
Ramos F, Thépot S, Pleyer L, Maurillo L, Itzykson R, Bargay J, Stauder R, Venditti A, Seegers V, Martínez-Robles V, Burgstaller S, Récher C, Debén G, Gaidano G, Gardin C, Musto P, Greil R, Sánchez-Guijo F, Fenaux P. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction. Leuk Res 2014; 39:296-306. [PMID: 25601157 DOI: 10.1016/j.leukres.2014.12.013] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2014] [Revised: 11/02/2014] [Accepted: 12/22/2014] [Indexed: 01/03/2023]
Abstract
Hypomethylating agents are able to prolong the overall survival of some patients diagnosed with acute myeloid leukemia. The aim of this study was to evaluate the clinical use of azacitidine as front-line therapy in unfit acute myeloid leukemia (AML) patients and to develop a clinical prediction model to identify which patients may benefit more from the drug. One hundred and ten untreated unfit AML patients received front-line azacitidine therapy in Spain, and response and survival were evaluated in them following European LeukemiaNet (ELN) guidelines. A clinical prediction rule was obtained from this population that was validated and refined in 261 patients treated in France, Austria and Italy. ELN response was achieved in 21.0% of the 371 patients (CI95% 17.0-25.5) and did not depend on bone marrow blast cell percentage. Median overall survival was 9.6 months (CI95% 8.5-10.8) and 40.6% of the patients were alive at 1 year (CI95% 35.5-45.7). European ALMA score (E-ALMA), based on performance status, white blood cell counts at azacitidine onset and cytogenetics, discriminated three risk groups with different survival and response rates. Azacitidine seems a reasonable therapeutic option for most unfit AML patients, i.e. those displaying a favorable or intermediate E-ALMA score.
Collapse
Affiliation(s)
- F Ramos
- Department of Hematology, University Hospital, León, Spain; Institute of Biomedicine (IBIOMED), University of León, Spain.
| | - S Thépot
- Department of Blood Diseases/Hematology, CHU, Angers, France
| | - L Pleyer
- 3rd Med. Dept. with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center; Paracelsus Medical University Hospital Salzburg, Austria
| | - L Maurillo
- Department of Hematology, Tor Vergata Foundation Polyclinic, University of Rome, Italy
| | - R Itzykson
- Department of Hematology, Saint Louis Hospital Paris VII University (APHP), France
| | - J Bargay
- Department of Hematology, Son Llatzer Hospital, Palma de Mallorca, Spain
| | - R Stauder
- Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria
| | - A Venditti
- Department of Hematology, Tor Vergata Foundation Polyclinic, University of Rome, Italy
| | - V Seegers
- Department of Hematology, Avicenne Hospital, Paris XIII University (APHP), Bobigny, France
| | | | - S Burgstaller
- Department of Internal Medicine IV, Wels-Grieskirchen Hospital, Wels, Austria
| | - C Récher
- Department of Hematology, CHU, Toulouse, France
| | - G Debén
- Department of Hematology, University Hospital, A Coruña, Spain
| | - G Gaidano
- Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
| | - C Gardin
- Department of Hematology, Avicenne Hospital, Paris XIII University (APHP), Bobigny, France
| | - P Musto
- Scientific Direction, IRCCS; Referral Cancer Center of Basilicata, Rionero in Vulture, Italy
| | - R Greil
- 3rd Med. Dept. with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center; Paracelsus Medical University Hospital Salzburg, Austria
| | - F Sánchez-Guijo
- Department of Hematology, University Hospital, Salamanca, Spain
| | - P Fenaux
- Department of Hematology, Saint Louis Hospital Paris VII University (APHP), France
| | | |
Collapse
|
5
|
Braun T, Cherait A, Rigal M, Bréchignac S, Thépot S, Gardin C, Adès L, Fenaux P. P-283 Efficacy of salvage with decitabine (DAC) for high-risk (HR)-MDS and advanced CMML after azacitidine (AZA) treatment failure. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70330-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
6
|
Itzykson R, Thépot S, Beyne-Rauzy O, Ame S, Isnard F, Dreyfus F, Salanoubat C, Taksin AL, Chelgoum Y, Berthon C, Malfuson JV, Legros L, Vey N, Turlure P, Gardin C, Boehrer S, Ades L, Fenaux P. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine? Leuk Res 2011; 36:397-400. [PMID: 22177456 DOI: 10.1016/j.leukres.2011.11.019] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2011] [Revised: 11/10/2011] [Accepted: 11/24/2011] [Indexed: 11/25/2022]
Abstract
We studied a retrospective cohort of 282 higher-risk MDS treated with azacitidine, including 32 patients who concomitantly received an ESA for a median of 5.8 months after azacitidine onset. Forty-four percent of ESA and 29% of no-ESA patients reached HI-E (p=0.07); 48% and 20% achieved transfusion independence (p=0.01). Median OS was 19.6 months in the ESA and 11.9 months in the no-ESA groups (p=0.04). Addition of an ESA significantly improved OS (p=0.03) independently of azacitidine schedule and duration, and of our proposed azacitidine risk score (Blood 2011;117:403-11). Adding an ESA to azacitidine in higher-risk MDS should be studied prospectively.
Collapse
Affiliation(s)
- R Itzykson
- Service d'Hématogie Clinique Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, and Paris 13 University, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Itzykson R, Thépot S, Eclache V, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Boehrer S, Gardin C, Adès L, Fenaux P. Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine. Leukemia 2011; 25:1207-9. [DOI: 10.1038/leu.2011.63] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
8
|
Gardin C, Itzykson R, Thépot S, Recher C, Marfaing A, Beyne-Rauzy O, Boehrer S, Dreyfus F, Fenaux P, Dombret H. Frontline azacitidine (AZA) or intensive chemotherapy (ICTx) in older AML patients. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.6530] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|